Women’s Health Breakthroughs: Alzheimer’s, HIV, UTIs, and More
🚺 This week’s Women’s Health Update delivers the latest on ground-breaking treatments, major policy shifts, and exciting developments in women’s health.
🔬 Key highlights:
💥 BioXcel’s BXCL501 achieves a major milestone for at-home use, showing safety and effectiveness in treating agitation in bipolar disorder and schizophrenia patients.
💉 FDA approves LEQEMBI IQLIK, a subcutaneous version of lecanemab, for maintenance treatment in Alzheimer’s patients, offering a more convenient option for continued care.
💊 Gilead’s Yeytuo receives European approval as the first twice-yearly injectable HIV prevention treatment, with near-zero infection rates in clinical trials.
🩺 AbbVie acquires Gilgamesh Pharmaceuticals to develop bretisilocin, a psychedelic compound with promising results for treating major depressive disorder.
🚨 Iterum launches Orlynvah, the first new branded treatment for uncomplicated UTIs in 25 years, addressing growing antibiotic resistance.
🔬 Japan moves to sell emergency contraception over-the-counter, improving access to reproductive healthcare services and increasing convenience for women.
🧠 Denmark issues a formal apology for the forced contraception of Greenlandic women between 1966 and 1970, acknowledging historical injustice.
📉 CVS holds off on adding Gilead’s HIV prevention shot Yeztugo to its coverage lists, despite its proven near-zero infection rate in trials.
🧪 Reunion Neuroscience shows promising Phase 2 results for RE104, a psychedelic drug targeting postpartum depression with lasting effects from a single injection.
📢 Stay Ahead in Women’s Health Research!
✅ Like, share, and subscribe for weekly updates on women’s health, neurology, and innovative therapies.
#WomensHealth #AlzheimersTreatment #HIVPrevention #UTITreatment #PsychedelicTherapies #MentalHealth #ReproductiveHealth #HealthcareInnovation #MedicalNews #LucidQuest #ClinicalTrials #Pharmaceuticals